The inspection was conducted by the Finnish Medicines Agency on behalf of EMA from March 10 to March 14 and it concluded with ...

Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the European Medicines Agency (EMA) has started a review of Valneva’s single-dose live attenuated ...

Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin” or the "Company”), a late-stage pharmaceutical company with a broad ...

today announced that the European Medicines Agency (EMA) has approved its Clinical Trial Application (CTA) to conduct its pivotal Phase 2B/3, multi-center, randomized, double-blind, placebo ...

Few areas of healthcare are as sensitive as cancer treatment. Each year, around 44,000 cancer tumours are diagnosed here.

Adds nine additional countries to the Company's ongoing pivotal Phase 3 trial; Authorization granted in all EU countries requested Enrollment and dosing underway in Phase 3 clinical trial (the "MIRACL ...

Morningstar brands and products Company Portfolio ...

The medicine will remain on the shelves but will come with additional warnings about the side effects, which appear to be ...

Of the 56 oncology medicines which were granted a European Medicines Agency (EMA) licence since 2020, only 14, or 25%, are currently available in Ireland. Cancer patients in Ireland continue to ...

The European Medicines Agency has recommended marketing approval for Alyftrek for cystic fibrosis and Attrogy for a form of hereditary amyloidosis.